{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,24]],"date-time":"2026-08-24T03:20:17Z","timestamp":1787541617601,"version":"build-2736575974"},"reference-count":34,"publisher":"Springer Science and Business Media LLC","issue":"8","license":[{"start":{"date-parts":[[2026,3,21]],"date-time":"2026-03-21T00:00:00Z","timestamp":1774051200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2026,3,21]],"date-time":"2026-03-21T00:00:00Z","timestamp":1774051200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Dig Dis Sci"],"published-print":{"date-parts":[[2026,8]]},"DOI":"10.1007\/s10620-026-09846-1","type":"journal-article","created":{"date-parts":[[2026,3,21]],"date-time":"2026-03-21T17:20:57Z","timestamp":1774113657000},"page":"3832-3843","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["Efficacy of Olezarsen in Severe Hypertriglyceridemia and Acute Pancreatitis Risk: A Systematic Review and Meta-Analysis of Randomized Controlled Trials"],"prefix":"10.1007","volume":"71","author":[{"ORCID":"https:\/\/orcid.org\/0009-0003-9414-360X","authenticated-orcid":false,"given":"Abdul","family":"Rehman","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dhvanit","family":"Rajdeep","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jonathan D.","family":"Mohnkern","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jacopo","family":"Lin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,3,21]]},"reference":[{"key":"9846_CR1","doi-asserted-by":"publisher","first-page":"1286","DOI":"10.1055\/a-1516-2661","volume":"147","author":"M Merkel","year":"2022","unstructured":"Merkel M, M\u00fcller-Wieland D, Laufs U, Parhofer KG. Triglyzeride \u2013 Aktuelle Bewertung als Risikomarker und Therapieziele. Dtsch Med Wochenschr. 2022;147:1286\u20131295. https:\/\/doi.org\/10.1055\/a-1516-2661.","journal-title":"Dtsch Med Wochenschr."},{"key":"9846_CR2","doi-asserted-by":"publisher","first-page":"99","DOI":"10.1093\/eurheartj\/ehz785","volume":"41","author":"U Laufs","year":"2020","unstructured":"Laufs U, Parhofer KG, Ginsberg HN, Hegele RA. Clinical review on triglycerides. European Heart Journal. 2020;41:99\u2013109c. https:\/\/doi.org\/10.1093\/eurheartj\/ehz785.","journal-title":"European Heart Journal."},{"key":"9846_CR3","doi-asserted-by":"publisher","first-page":"891","DOI":"10.1016\/j.amjcard.2010.11.008","volume":"107","author":"JB Christian","year":"2011","unstructured":"Christian JB, Bourgeois N, Snipes R, Lowe KA. Prevalence of Severe (500 to 2,000 mg\/dl) Hypertriglyceridemia in United States Adults. The American Journal of Cardiology. 2011;107:891\u2013897. https:\/\/doi.org\/10.1016\/j.amjcard.2010.11.008.","journal-title":"The American Journal of Cardiology."},{"key":"9846_CR4","doi-asserted-by":"publisher","first-page":"100932","DOI":"10.1016\/j.jacadv.2024.100932","volume":"3","author":"C Gurevitz","year":"2024","unstructured":"Gurevitz C, Chen L, Muntner P, Rosenson RS. Hypertriglyceridemia and multiorgan disease among U.S. Adults. JACC: Advances. 2024;3:100932. https:\/\/doi.org\/10.1016\/j.jacadv.2024.100932.","journal-title":"JACC: Advances."},{"key":"9846_CR5","doi-asserted-by":"publisher","first-page":"1497","DOI":"10.1038\/ajg.2015.261","volume":"110","author":"H Nawaz","year":"2015","unstructured":"Nawaz H, Koutroumpakis E, Easler J et al. Elevated Serum Triglycerides are independently associated with persistent organ failure in acute pancreatitis. American Journal of Gastroenterology. 2015;110:1497\u20131503. https:\/\/doi.org\/10.1038\/ajg.2015.261.","journal-title":"American Journal of Gastroenterology."},{"key":"9846_CR6","doi-asserted-by":"publisher","DOI":"10.1016\/j.ajpc.2024.100648","volume":"18","author":"A Filtz","year":"2024","unstructured":"Filtz A, Parihar S, Greenberg GS et al. New approaches to triglyceride reduction: is there any hope left? American Journal of Preventive Cardiology. 2024;18:100648. https:\/\/doi.org\/10.1016\/j.ajpc.2024.100648.","journal-title":"American Journal of Preventive Cardiology."},{"key":"9846_CR7","doi-asserted-by":"publisher","first-page":"42","DOI":"10.3390\/jcdd9020042","volume":"9","author":"I Parthymos","year":"2022","unstructured":"Parthymos I, Kostapanos MS, Liamis G, Florentin M. Early Investigational and experimental therapeutics for the treatment of hypertriglyceridemia. JCDD. 2022;9:42. https:\/\/doi.org\/10.3390\/jcdd9020042.","journal-title":"JCDD."},{"key":"9846_CR8","doi-asserted-by":"publisher","first-page":"1781","DOI":"10.1056\/NEJMoa2400201","volume":"390","author":"ESG Stroes","year":"2024","unstructured":"Stroes ESG, Alexander VJ, Karwatowska-Prokopczuk E et al. Olezarsen, acute pancreatitis, and familial chylomicronemia syndrome. N Engl J Med. 2024;390:1781\u20131792. https:\/\/doi.org\/10.1056\/NEJMoa2400201.","journal-title":"N Engl J Med."},{"key":"9846_CR9","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2512761","author":"NA Marston","year":"2025","unstructured":"Marston NA, Bergmark BA, Alexander VJ et al. Olezarsen for managing severe hypertriglyceridemia and pancreatitis risk. N Engl J Med. 2025. https:\/\/doi.org\/10.1056\/NEJMoa2512761.","journal-title":"N Engl J Med"},{"key":"9846_CR10","doi-asserted-by":"publisher","first-page":"5173","DOI":"10.1097\/MS9.0000000000003505","volume":"87","author":"T Ashraf","year":"2025","unstructured":"Ashraf T, Devi N, Aradhna F et al. The impact of olezarsen on hypertriglyceridemia in high cardiovascular risk patients: a systematic review, meta-analysis, and meta-regression. Ann Med Surg (Lond). 2025;87:5173\u20135184. https:\/\/doi.org\/10.1097\/MS9.0000000000003505.","journal-title":"Ann Med Surg (Lond)."},{"key":"9846_CR11","doi-asserted-by":"publisher","DOI":"10.1007\/s00210-025-04406-2","author":"I Serag","year":"2025","unstructured":"Serag I, Alkhawaldeh IM, Shati AA et al. Optimizing cardiovascular health: a systematic review and meta-analysis of olezarsen dosages in high-risk hypertriglyceridemic patients. Naunyn-Schmiedeberg\u2019s Arch Pharmacol. 2025. https:\/\/doi.org\/10.1007\/s00210-025-04406-2.","journal-title":"Naunyn-Schmiedeberg\u2019s Arch Pharmacol"},{"key":"9846_CR12","doi-asserted-by":"publisher","first-page":"574","DOI":"10.1097\/MJT.0000000000001877","volume":"32","author":"A Raja","year":"2025","unstructured":"Raja A, Shafique MA, Raja S et al. Olezarsen for hypertriglyceridemia in patients at high cardiovascular risk-a systematic review and meta analysis. Am J Ther. 2025;32:574\u2013577. https:\/\/doi.org\/10.1097\/MJT.0000000000001877.","journal-title":"Am J Ther."},{"key":"9846_CR13","doi-asserted-by":"publisher","first-page":"3","DOI":"10.37616\/2212-5043.1439","volume":"37","author":"CD Tristan","year":"2025","unstructured":"Tristan CD, Myrtha R, Wijayanto MA et al. Efficacy and safety of olezarsen in dyslipidemia: a systematic review and dose-response meta-analysis of randomized controlled trials. J Saudi Heart Assoc. 2025;37:3. https:\/\/doi.org\/10.37616\/2212-5043.1439.","journal-title":"J Saudi Heart Assoc."},{"key":"9846_CR14","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.n71","author":"MJ Page","year":"2021","unstructured":"Page MJ, McKenzie JE, Bossuyt PM et al. The PRISMA 2020 statement: an updated guideline for reporting systematic reviews. BMJ. 2021. https:\/\/doi.org\/10.1136\/bmj.n71.","journal-title":"BMJ"},{"key":"9846_CR15","unstructured":"Higgins JPT, Thomas J, Chandler J, Cumpston M, Li T, Page MJ, Welch VA (editors). Cochrane Handbook for Systematic Reviews of Interventions Version 6.5 Publisher: Cochrane 2024. https:\/\/www.cochrane.org\/handbook"},{"key":"9846_CR16","unstructured":"Higgins JPT, Thomas J, Chandler J, Cumpston M, Li T, Page MJ, Welch VA (editors). Cochrane Handbook for Systematic Reviews of Interventions Version 6.5 (2024) (version 7.3, Chapter 10, Section 10.4.4). In: Publisher: Cochrane 2024. https:\/\/www.cochrane.org\/handbook"},{"key":"9846_CR17","unstructured":"Higgins JPT, Thomas J, Chandler J, Cumpston M, Li T, Page MJ, Welch VA (editors). Cochrane Handbook for Systematic Reviews of Interventions Version 6.5 (2024) (version 7.3, Chapter 10, Section 10.3). In: Publisher: Cochrane 2024. https:\/\/www.cochrane.org\/handbook"},{"key":"9846_CR18","doi-asserted-by":"publisher","first-page":"102","DOI":"10.1136\/gutjnl-2012-302779","volume":"62","author":"PA Banks","year":"2013","unstructured":"Banks PA, Bollen TL, Dervenis C et al. Classification of acute pancreatitis\u20142012: revision of the Atlanta classification and definitions by international consensus. Gut. 2013;62:102\u2013111. https:\/\/doi.org\/10.1136\/gutjnl-2012-302779.","journal-title":"Gut."},{"key":"9846_CR19","doi-asserted-by":"publisher","first-page":"1401","DOI":"10.1093\/eurheartj\/ehab820","volume":"43","author":"JC Tardif","year":"2022","unstructured":"Tardif JC, Karwatowska-Prokopczuk E, Amour ES et al. Apolipoprotein C-III reduction in subjects with moderate hypertriglyceridaemia and at high cardiovascular risk. European Heart Journal. 2022;43:1401\u20131412. https:\/\/doi.org\/10.1093\/eurheartj\/ehab820.","journal-title":"European Heart Journal."},{"key":"9846_CR20","doi-asserted-by":"publisher","first-page":"617","DOI":"10.1016\/j.jacl.2022.06.005","volume":"16","author":"E Karwatowska-Prokopczuk","year":"2022","unstructured":"Karwatowska-Prokopczuk E, Tardif JC, Gaudet D et al. Effect of olezarsen targeting APOC-III on lipoprotein size and particle number measured by NMR in patients with hypertriglyceridemia. Journal of Clinical Lipidology. 2022;16:617\u2013625. https:\/\/doi.org\/10.1016\/j.jacl.2022.06.005.","journal-title":"Journal of Clinical Lipidology."},{"key":"9846_CR21","doi-asserted-by":"publisher","first-page":"795","DOI":"10.1016\/j.pan.2020.06.005","volume":"20","author":"AL Yang","year":"2020","unstructured":"Yang AL, McNabb-Baltar J. Hypertriglyceridemia and acute pancreatitis. Pancreatology. 2020;20:795\u2013800. https:\/\/doi.org\/10.1016\/j.pan.2020.06.005.","journal-title":"Pancreatology."},{"key":"9846_CR22","doi-asserted-by":"publisher","first-page":"2265939","DOI":"10.1080\/07853890.2023.2265939","volume":"55","author":"M Qiu","year":"2023","unstructured":"Qiu M, Zhou X, Zippi M et al. Comprehensive review on the pathogenesis of hypertriglyceridaemia-associated acute pancreatitis. Annals of Medicine. 2023;55:2265939. https:\/\/doi.org\/10.1080\/07853890.2023.2265939.","journal-title":"Annals of Medicine."},{"key":"9846_CR23","doi-asserted-by":"publisher","first-page":"117","DOI":"10.1007\/s44337-025-00329-2","volume":"2","author":"MN Saddique","year":"2025","unstructured":"Saddique MN, Thapa R, Khan Y et al. Efficacy and safety of Olezarsen in treating hypertriglyceridemia: a systematic review and meta-analysis of randomized controlled trials. Discov Med. 2025;2:117. https:\/\/doi.org\/10.1007\/s44337-025-00329-2.","journal-title":"Discov Med."},{"key":"9846_CR24","doi-asserted-by":"publisher","first-page":"427","DOI":"10.1016\/j.jacc.2012.08.1026","volume":"61","author":"A Varbo","year":"2013","unstructured":"Varbo A, Benn M, Tybj\u00e6rg-Hansen A, J\u00f8rgensen AB, Frikke-Schmidt R, Nordestgaard BG. Remnant cholesterol as a causal risk factor for ischemic heart disease. J Am Coll Cardiol. 2013;61:427\u2013436. https:\/\/doi.org\/10.1016\/j.jacc.2012.08.1026.","journal-title":"J Am Coll Cardiol."},{"key":"9846_CR25","doi-asserted-by":"publisher","first-page":"660","DOI":"10.1161\/ATVBAHA.117.310473","volume":"38","author":"AB Wulff","year":"2018","unstructured":"Wulff AB, Nordestgaard BG, Tybj\u00e6rg-Hansen A. APOC3 Loss-of-Function Mutations, Remnant Cholesterol, Low-Density Lipoprotein Cholesterol, and Cardiovascular Risk: Mediation- and Meta-Analyses of 137 895 Individuals. ATVB. 2018;38:660\u2013668. https:\/\/doi.org\/10.1161\/ATVBAHA.117.310473.","journal-title":"ATVB."},{"key":"9846_CR26","doi-asserted-by":"publisher","first-page":"1923","DOI":"10.1056\/NEJMoa2210645","volume":"387","author":"A Das Pradhan","year":"2022","unstructured":"Das Pradhan A, Glynn RJ, Fruchart JC et al. Triglyceride lowering with pemafibrate to reduce cardiovascular risk. N Engl J Med. 2022;387:1923\u20131934. https:\/\/doi.org\/10.1056\/NEJMoa2210645.","journal-title":"N Engl J Med."},{"key":"9846_CR27","doi-asserted-by":"publisher","first-page":"898","DOI":"10.2337\/dc21-1288","volume":"45","author":"HN Ginsberg","year":"2022","unstructured":"Ginsberg HN, Hounslow NJ, Senko Y et al. Efficacy and safety of K-877 (Pemafibrate), a selective PPAR\u03b1 modulator, in European patients on statin therapy. Diabetes Care. 2022;45:898\u2013908. https:\/\/doi.org\/10.2337\/dc21-1288.","journal-title":"Diabetes Care."},{"key":"9846_CR28","doi-asserted-by":"publisher","first-page":"2255","DOI":"10.1056\/NEJMoa1107579","volume":"365","author":"The AIM-HIGH Investigators","year":"2011","unstructured":"The AIM-HIGH Investigators. Niacin in patients with low HDL cholesterol levels receiving intensive statin therapy. N Engl J Med. 2011;365:2255\u20132267. https:\/\/doi.org\/10.1056\/NEJMoa1107579.","journal-title":"N Engl J Med."},{"key":"9846_CR29","doi-asserted-by":"publisher","first-page":"1563","DOI":"10.1056\/NEJMoa1001282","volume":"362","author":"N Ginsberg Henry","year":"2010","unstructured":"Ginsberg Henry N, Elam Marshall B, Lovato Laura C. Effects of Combination lipid therapy in type 2 diabetes mellitus. N Engl J Med. 2010;362:1563\u20131574. https:\/\/doi.org\/10.1056\/NEJMoa1001282.","journal-title":"N Engl J Med."},{"key":"9846_CR30","doi-asserted-by":"publisher","DOI":"10.1056\/EVIDoa2200325","author":"D Gaudet","year":"2023","unstructured":"Gaudet D, Clifton P, Sullivan D et al. RNA interference therapy targeting apolipoprotein C-III in hypertriglyceridemia. NEJM Evidence. 2023. https:\/\/doi.org\/10.1056\/EVIDoa2200325.","journal-title":"NEJM Evidence"},{"key":"9846_CR31","doi-asserted-by":"publisher","first-page":"982","DOI":"10.3390\/jcm11040982","volume":"11","author":"G Kolovou","year":"2022","unstructured":"Kolovou G, Kolovou V, Katsiki N. Volanesorsen: a new Era in the treatment of severe hypertriglyceridemia. JCM. 2022;11:982. https:\/\/doi.org\/10.3390\/jcm11040982.","journal-title":"JCM."},{"key":"9846_CR32","doi-asserted-by":"publisher","first-page":"2200","DOI":"10.1056\/NEJMoa1400284","volume":"371","author":"D Gaudet","year":"2014","unstructured":"Gaudet D, Brisson D, Tremblay K et al. Targeting APOC3 in the familial chylomicronemia syndrome. N Engl J Med. 2014;371:2200\u20132206. https:\/\/doi.org\/10.1056\/NEJMoa1400284.","journal-title":"N Engl J Med."},{"key":"9846_CR33","doi-asserted-by":"publisher","first-page":"531","DOI":"10.1056\/NEJMoa1715944","volume":"381","author":"JL Witztum","year":"2019","unstructured":"Witztum JL, Gaudet D, Freedman SD et al. Volanesorsen and triglyceride levels in familial chylomicronemia syndrome. N Engl J Med. 2019;381:531\u2013542. https:\/\/doi.org\/10.1056\/NEJMoa1715944.","journal-title":"N Engl J Med."},{"key":"9846_CR34","doi-asserted-by":"publisher","first-page":"2623","DOI":"10.2147\/DDDT.S224771","volume":"14","author":"O Esan","year":"2020","unstructured":"Esan O, Wierzbicki AS. Volanesorsen in the treatment of familial chylomicronemia syndrome or hypertriglyceridaemia: design. Development and Place in Therapy. DDDT. 2020;14:2623\u20132636. https:\/\/doi.org\/10.2147\/DDDT.S224771.","journal-title":"Development and Place in Therapy. DDDT."}],"container-title":["Digestive Diseases and Sciences"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10620-026-09846-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s10620-026-09846-1","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10620-026-09846-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,24]],"date-time":"2026-08-24T03:00:55Z","timestamp":1787540455000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s10620-026-09846-1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,3,21]]},"references-count":34,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2026,8]]}},"alternative-id":["9846"],"URL":"https:\/\/doi.org\/10.1007\/s10620-026-09846-1","relation":{"has-preprint":[{"id-type":"doi","id":"10.21203\/rs.3.rs-8583537\/v1","asserted-by":"object"}]},"ISSN":["0163-2116","1573-2568"],"issn-type":[{"value":"0163-2116","type":"print"},{"value":"1573-2568","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,3,21]]},"assertion":[{"value":"12 January 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"13 March 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"21 March 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing interests.","order":1,"name":"Ethics","label":"Conflict of interest","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This study is a systematic review and meta-analysis of previously published studies. No new human or animal subjects were involved, and therefore institutional review board approval and informed consent were not required.","order":2,"name":"Ethics","label":"Ethical approval","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors affirm adherence to the guidelines of the committee on publication ethics (COPE) and the recommendations of the international committee of medical journal editors (ICMJE), defining the role of authors and contributors.","order":3,"name":"Ethics","label":"Publication ethical statement","group":{"name":"EthicsHeading","label":"Declarations"}}]}}